Abstract
Beyond allopurinol and the well-established uricosuric drugs, several other agents can decrease serum uric acid (SUA) levels, such as losartan, fenofibrate and some non-steroidal anti-inflammatory drugs (NSAIDs). Some of these drugs increase renal urate excretion. Hyperuricaemia and gout are common problems (at least 1% of Western men are affected by gout). Raised SUA levels increase the incidence of acute gout and renal calculi. Hyperuricaemia may also predict an increased risk of vascular events. Therefore, lowering SUA levels is of clinical relevance. In this review we consider the effect on SUA levels of drugs that are prescribed for indications other than treating hyperuricaemia. These drugs may obviate the need for specific treatment (e.g. allopurinol) aimed at lowering SUA levels. Furthermore, because hyperuricaemic patients may already be on several drugs (e.g. due to associated dyslipidaemia, hypertension and/or arthritis) compliance may be improved by avoiding additional medication. The potential for adverse effects associated with polypharmacy would also be decreased.
Keywords: Uric acid, urate, uricosuric, fenofibrate, losartan, NSAID, diuretic, atorvastatin
Current Pharmaceutical Design
Title: Effect on Serum Uric Acid Levels of Drugs Prescribed for Indications other than Treating Hyperuricaemia
Volume: 11 Issue: 32
Author(s): S. S. Daskalopoulou, V. Tzovaras, D. P. Mikhailidis and M. Elisaf
Affiliation:
Keywords: Uric acid, urate, uricosuric, fenofibrate, losartan, NSAID, diuretic, atorvastatin
Abstract: Beyond allopurinol and the well-established uricosuric drugs, several other agents can decrease serum uric acid (SUA) levels, such as losartan, fenofibrate and some non-steroidal anti-inflammatory drugs (NSAIDs). Some of these drugs increase renal urate excretion. Hyperuricaemia and gout are common problems (at least 1% of Western men are affected by gout). Raised SUA levels increase the incidence of acute gout and renal calculi. Hyperuricaemia may also predict an increased risk of vascular events. Therefore, lowering SUA levels is of clinical relevance. In this review we consider the effect on SUA levels of drugs that are prescribed for indications other than treating hyperuricaemia. These drugs may obviate the need for specific treatment (e.g. allopurinol) aimed at lowering SUA levels. Furthermore, because hyperuricaemic patients may already be on several drugs (e.g. due to associated dyslipidaemia, hypertension and/or arthritis) compliance may be improved by avoiding additional medication. The potential for adverse effects associated with polypharmacy would also be decreased.
Export Options
About this article
Cite this article as:
Daskalopoulou S. S., Tzovaras V., Mikhailidis P. D. and Elisaf M., Effect on Serum Uric Acid Levels of Drugs Prescribed for Indications other than Treating Hyperuricaemia, Current Pharmaceutical Design 2005; 11 (32) . https://dx.doi.org/10.2174/138161205774913309
DOI https://dx.doi.org/10.2174/138161205774913309 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adiposity and Alzheimers Disease
Current Alzheimer Research A Review of the Therapeutic Benefits of Moringa oleifera in Controlling High Blood Pressure (Hypertension)
Current Traditional Medicine Vitamins in Heart Failure: Friend or Enemy?
Current Pharmaceutical Design Complement Activation-Related Pseudoallergy Caused by Amphiphilic Drug Carriers: The Role of Lipoproteins
Current Drug Delivery Red Wine Consumption and Prevention of Atherosclerosis: An In Vitro Model Using Human Peripheral Blood Mononuclear Cells
Current Pharmaceutical Design Advanced Glycation End Products: A Link Between Periodontitis and Diabetes Mellitus?
Current Diabetes Reviews Dietary Carotenoids in Managing Metabolic Syndrome and Role of PPARs in the Process
Current Nutrition & Food Science Diabetes, Cognitive Function, and the Blood-Brain Barrier
Current Pharmaceutical Design The Role of Renal Nerve Ablation for the Management of Resistant Hypertension and other Disease Conditions: Benefits and Concerns
Current Vascular Pharmacology Hypertensive Versus HIV-infected Patients: Who Has the Greatest Target Organ Damage? Comparison of Carotid Plaque Prevalence, Intima Media Thickness and Renal Resistive Index in the Two Groups of Patients
Current Hypertension Reviews The Effects of Obesity on the Cerebral Vasculature
Current Vascular Pharmacology Treating Hypertension in the Elderly: Common Problems and Solutions
Current Hypertension Reviews Secondary Hypertension: The Ways of Management
Current Vascular Pharmacology Is Renalase a Novel Player in Catecholaminergic Signaling? The Mystery of the Catalytic Activity of an Intriguing New Flavoenzyme
Current Pharmaceutical Design Marine Food Protection in Testicular Damages Caused by Diabetes Mellitus
Current Diabetes Reviews Interaction of Cyclosporine A and the Renin-Angiotensin System New Perspectives
Current Drug Metabolism The Medicinal Chemistry of Nitrite as a Source of Nitric Oxide Signaling
Current Topics in Medicinal Chemistry Mast Cells and Basophils: Trojan Horses of Conventional Lin- Stem/Progenitor Cell Isolates
Current Pharmaceutical Design Detecting the Association Between Residual Thrombus and Post-thrombotic Classification of Chronic Venous Disease with Range Regression
Reviews on Recent Clinical Trials Effects of Compounds from Passiflora edulis Sims f. flavicarpa Juice on Blood Coagulation and on Proteolytic Enzymes
Protein & Peptide Letters